Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)

Fasching P, Neven P, Jerusalem G, Beck JT, Chan A, De Laurentiis M, Bianchi GV, Martin Jimenez M, Chia S, Gaur A, Sondhi M, Rodriguez-Lorenc K, Lanoue B, Chandiwana D, Nusch A (2020)

Publication Type: Conference contribution

Publication year: 2020

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S67-S68

Conference Proceedings Title: ANNALS OF ONCOLOGY

Event location: ONLINE

DOI: 10.1016/j.annonc.2020.03.245

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Universidad Complutense de Madrid (UCM) ES Spain (ES) Novartis AG CH Switzerland (CH) University Hospital Leuven (UZ) / Universitaire ziekenhuizen Leuven BE Belgium (BE) Curtin University AU Australia (AU) Centre Hospitalier Universitaire de Liège (CHU Liège) BE Belgium (BE) Fondazione IRCCS: Istituto Nazionale dei Tumori IT Italy (IT) British Columbia Cancer Agency CA Canada (CA) Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT Italy (IT) Highlands Oncology Group US United States (USA) (US)

How to cite

APA:

Fasching, P., Neven, P., Jerusalem, G., Beck, J.T., Chan, A., De Laurentiis, M.,... Nusch, A. (2020). Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3). In ANNALS OF ONCOLOGY (pp. S67-S68). ONLINE: AMSTERDAM: ELSEVIER.

MLA:

Fasching, Peter, et al. "Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib (RIB) plus fulvestrant (FUL) as first-line (1L) and second-line (2L) therapy in MONALEESA-3 (ML-3)." Proceedings of the ESMO Breast Cancer Virtual Meeting, ONLINE AMSTERDAM: ELSEVIER, 2020. S67-S68.

BibTeX: Download